×
About 146,930 results

SAFE-PAD shows long-term safety of paclitaxel devices
https://www.mdedge.com/cardiology/article/254856/interventional-cardiology-surgery/safe-pad-shows-long-term-safety
Richard Mark Kirkner

May 23rd, 2022 - Patients who have paclitaxel-coated stents and balloons have survival and outcomes comparable to those who have a bare-metal stent or percutaneous transluminal angioplasty, according to updated results from a large study of almost 170,000 Medicare beneficiaries. The SAFE-PAD study analyzed Medicare claims data of 168,533 patients, including 70,584 who were treated with drug-coated devices (DCD).

National Poll: Safety not always top of mind for parents choosing kids' summer camps
https://www.eurekalert.org/news-releases/953285

May 23rd, 2022 - When it comes to picking a summer camp for kids, logistics top the checklist for most parents, a new national poll suggests. And while families consider health and safety information, such as camp supervision and first aid training, less than half of parents rate general safety policies as essential to their camp decision, according to the University of Michigan Health C.S. Mott Children’s Hosp...

Liver transplants from drug overdose deaths rose sharply during COVID-19 pandemic
https://www.eurekalert.org/news-releases/953177

May 22nd, 2022 - San Diego, CA (May 22, 2022) — Liver transplants from drug overdose donors rose significantly in the pandemic’s first year, helping keep the number of liver transplants in the U.S. stable despite COVID-19 disruptions, according to a study to be presented at Digestive Disease Week® (DDW) 2022. “When the pandemic began, we saw no decline in liver transplants, which seemed surprising since many su...

European committee recommends approval of baricitinib for severe alopecia areata
https://www.mdedge.com/dermatology/article/254805/hair-nails/european-committee-recommends-approval-baricitinib-severe
Doug Brunk

May 20th, 2022 - The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of baricitinib, a Janus kinase (JAK) inhibitor, for the treatment of adults with severe alopecia areata (AA). The development, which was announced in a May 20, 2022, press release from the manufacturer, Eli Lilly and Incyte, marks the first step toward European regulatory approva.

FAQs on Philips Respironics Ventilator, BiPAP Machine, and CPAP Machine Recalls
https://www.fda.gov/medical-devices/safety-communications/faqs-philips-respironics-ventilator-bipap-machine-and-cpap-machine-recalls
MedWatch; FDA

May 20th, 2022 - UPDATE: On May 19, 2022, the FDA updated this web page to help ensure patients and providers have important information about the recall of these critical devices. See What the FDA is Doing for more information. Philips Respironics (Philips) voluntarily recalled certain ventilators, bi-level positive airway pressure (also known as Bilevel PAP, BiPAP, or BPAP) machines, and continuous positive a...

Update: Certain Philips Respironics Ventilators, BiPAP Machines, and CPAP Machines Reca...
https://www.fda.gov/medical-devices/safety-communications/update-certain-philips-respironics-ventilators-bipap-machines-and-cpap-machines-recalled-due
MedWatch; FDA

May 20th, 2022 - UPDATE: On May 19, 2022, the FDA updated this safety communication to provide the latest information about medical device reports (MDRs) associated with the breakdown of the polyester-based polyurethane (PE-PUR) foam used in the Philips Respironics ventilator, BiPAP machine, and CPAP machine recalls. In addition, the FDA has taken additional actions since this updated safety communication was i...

SterRx, LLC Issues Voluntary Nationwide Recall of Sodium Bicarbonate in 5% Dextrose Inj...
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sterrx-llc-issues-voluntary-nationwide-recall-sodium-bicarbonate-5-dextrose-injection-150meq-1000-ml
MedWatch; FDA

May 20th, 2022 - SterRx, LLC today announced the voluntary nationwide recall of three lots of Sodium Bicarbonate in 5% Dextrose Injection 150mEq per 1,000 mL due to waterborne microbial contamination. SterRx, LLC has initiated this voluntary recall of Sodium Bicarbonate injection, to the Hospital Pharmacy level. Intravenous administration of Sodium Bicarbonate in 5% Dextrose Injection 150mEq per 1,000 mL, inten...

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sam...
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/allergan-issues-nationwide-voluntary-recall-taytullar-softgel-capsules-1mg20mcg-sample-packs-due-out
MedWatch; FDA

May 20th, 2022 - Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians sample pack, indicated for use by women to prevent pregnancy. Allergan recently identified, through a physician report, that four placebo capsules were plac...

Medical debt during pandemic
https://www.eurekalert.org/news-releases/953336

May 20th, 2022 - About The Study: Researchers found no evidence of a net association between the COVID-19 pandemic and medical debt, overall or across areas with different incomes and pandemic severity, results that are consistent with any increase being offset by decreases in elective medical procedures and new health care–related governmental policies. Authors: Neale Mahoney, Ph.D., of Stanford University in ...

Venous thromboembolism: Less recurrencies with low-dose apixaban compared to discontinuation of the anticoagulant after negative D-dimer
https://www.eurekalert.org/news-releases/953406

May 20th, 2022 - Bologna 8 April 2022 - Patients who have suffered from a first episode of unprovoked venous thromboembolism (VTE) have an eight times higher risk of recurrence if they stop treatment after repeated negative D-dimer tests, instead of continuing with low-dose anticoagulant (apixaban). These are the results of the APIDULCIS study presented at the 6th Conference of the Arianna Anticoagulation Found...

Long term use of clopidogrel monotherapy associated with lower patient risk compared to aspirin monotherapy
https://www.eurekalert.org/news-releases/953214

May 20th, 2022 - ATLANTA, GA (May 20, 2022) – Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin monotherapy beyond 12 months after PCI in high-risk patients during the chronic maintenance period. This study found that clopidogrel monotherapy was associated with reduced risk of net adverse clinical events (NACE; all-cause death, MI, stent thrombosis, stroke, or ...

No-implant interatrial shunt device to treat heart failure patients reveals promising multi-center clinical data
https://www.eurekalert.org/news-releases/953211

May 20th, 2022 - ATLANTA, GA (May 20, 2022) – Results from early clinical evaluation of the Alleviant System to treat heart failure patients with preserved and reduced ejection fraction (HFpEF and HFrEF) was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions. This multi-center evaluation across three trial programs (AL...

New long-term data of paclitaxel devices continues to show no increased mortality compared to non-drug coated devices
https://www.eurekalert.org/news-releases/953209

May 20th, 2022 - ATLANTA, GA (May 20, 2022) – New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-coated Devices (SAFE-PAD) study were presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions. The analysis found no meaningful difference in survival between patients treated ...

Assessing bias in patient safety reporting by physician gender, race, ethnicity, faculty rank
https://www.eurekalert.org/news-releases/953337

May 20th, 2022 - About The Study: This study of 401 patient safety reports examined whether there is bias in how events are reported based on the race and ethnicity, gender or faculty rank of the physician who is the subject of the event report. Authors: Elan Burton, M.D., M.H.A., of the Stanford University School of Medicine in Palo Alto, California, is the corresponding author. To access the embargoed study: ...

US CDC Says COVID Vaccine-Related Myocarditis Much Lower for Children Than Teens
https://www.medscape.com/viewarticle/974285

May 20th, 2022 - NEW YORK (Reuters) - The U.S. Centers for Diseases Control and Prevention (CDC) on Thursday said rates of reported heart inflammation linked to the Pfizer/BioNTech COVID-19 vaccine have been much lower in 5- to 11-year-old boys than in adolescents and young men, and were only slightly elevated above normal. The agency, in a presentation to an advisory committee discussing on the need for booste...

AYA Leukemia Survivors: 'Cure Is Not Enough'
https://www.medscape.com/viewarticle/974337

May 20th, 2022 - Although adolescents and young adults (AYAs) who survive leukemia are living much longer than ever before, their life spans are still shorter than those of the general population, a new study concludes. The study found that the 10-year survival of AYA leukemia survivors was approximately 10% lower than that of the age-adjusted US general population at large. These differences persisted for up t...

Concerns Over Mandatory Overtime for Nurses Increased During Pandemic
https://www.medscape.com/viewarticle/974355

May 20th, 2022 - Nurse fatigue was a concern long before March 2020, but the pandemic has spurred more discussions about the effects that long hours and mandatory overtime have on patient safety and employee well-being. When an internal memo from the University Medical Center of Southern Nevada circulated online recently, detailing the hospital's plans to enact mandatory overtime, the pushback was immediate and...

Baricitinib Recommended for Approval of Severe Alopecia Areata in Europe
https://www.medscape.com/viewarticle/974368

May 20th, 2022 - The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of baricitinib, a Janus kinase (JAK) inhibitor, for the treatment of adults with severe alopecia areata (AA). The development, which was announced in a May 20, 2022, press release from the manufacturer, Eli Lilly and Incyte, marks the first step toward European regulatory approva...

New ASA Decision Tree Tool Helps Treat Difficult Airways
https://www.medscape.com/viewarticle/974369

May 20th, 2022 - A new decision tree tool guides anesthesiologists through managing patients with difficult airways by improving communication and identifying factors of concern, according to a report in Anesthesia & Analgesia.    "The American Society of Anesthesiologists (ASA) Task Force on Management of the Difficult Airway has developed a decision tree tool that uses inductive assessments to guide the anest...

Roe v. Wade's Pending Fall Raises Privacy Concerns
https://www.medscape.com/viewarticle/974371

May 20th, 2022 - If Roe v. Wade is overturned, can criminal prosecutors or tech companies use smartphone data against someone? Now that the future of U.S. abortion laws hangs in the balance, many women are questioning the degree of caution needed to keep their cyber activity confidential – especially period and fertility tracking apps, smartphone location data, and social media interactions. Cybersecurity and l...